Laslitec IV infusion 7.5mg, containing Rasburicase (genetically recombined), is manufactured by Sanofi. This injectable drug, with YJ code 3959415F2021 and standard 7.5mg x 1 bottle (with dissolving solution), is indicated for the management of high uric acid levels (hyperuricemia) in cancer patients receiving chemotherapy.
Laslitec IV infusion 7.5mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →